## **Special Issue**

# Biomarkers and Drug Candidates for the Treatment of Neuroinflammation

#### Message from the Guest Editors

Recent discoveries suggest that beside the traditional neuroinflammatory disorders, such as multiple sclerosis, neuroinflammation has an important contribution to the development and outcome of several other neurologic conditions and psychiatric disorders. However, the interplay between the immune system and the central nervous system (CNS) is very complex, allowing both adaptive and pathological immunological processes, and thus identifying the rapeutic targets are challenging and conditional on better understanding of neuroinflammatory disease mechanisms. ..... This Special Issue embracing research focusing on neuroinflammation and related biomarkers in order to identify drug candidates in the service of better understanding and treating neuropsychiatric disorders and aims to provide readers with the most recent advances in this field. Authors are invited to submit relevant original articles, reviews or short communications for inclusion.

#### **Guest Editors**

Dr. Gabriella Juhasz

Department of Pharmacodynamics, Faculty of Pharmaceutical Sciences, Semmelweis University, Budapest, Hungary

#### Dr. Xenia Gonda

- 1. Department of Psychiatry and Psychotherapy, Semmelweis University, 1085 Budapest, Hungary
- 2. Department of Clinical Psychology, Semmelweis University, 1092 Budapest, Hungary
- 3. NAP3.0 Neuropsychopharmacology Research Group, Hungarian Academy of Sciences and Semmelweis University, 1089 Budapest, Hungary

#### Deadline for manuscript submissions

closed (31 October 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/121927

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).